10 completed, 1 active not recruiting, 1 terminated, 1 unknown. 6 Phase 3, 3 Phase 4, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 4, Active not recruiting 1, Terminated 1 |
| Phase 4 | 3 | Completed 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 2 |
Follow Plegridy: new trials by email Literature Review of Plegridy trials Research Report on Plegridy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Containing Coronavirus Disease 19 (COVID-19) Trial Peginterferon beta-1a - SARS-CoV Infection, Interferon | Phase 3 | Completed | Pontificia Universidad Catolica de Chile | 1173 | 2020-12-01 | 2021-09-10 |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis BIIB017 (peginterferon beta-1a), Interferon beta type 1a - Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Active not recruiting | Biogen | 152 | 2019-10-18 | 2026-09-24 |
| Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants Dimethyl Fumarate, Peginterferon Beta-1a, Placebo - Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Terminated | Biogen | 11 | 2019-03-19 | 2023-06-15 |
| A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis SC Peginterferon beta-1a, SC interferon beta-1a, SC interferon beta-1b - Multiple Sclerosis, Relapsing-Remitting | Completed | Biogen | 626 | 2017-11-27 | 2019-09-25 | |
| Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects Plegridy, Prednisone, Tylenol Pill - Multiple Sclerosis | Phase 4 | Unknown | Holy Name Medical Center, Inc. | 50 | 2017-09-25 | 2019-08-15 |
| Plegridy Satisfaction Study in Participants peginterferon beta-1a - Relapsing-Remitting Multiple Sclerosis (RRMS) | Phase 4 | Completed | Biogen | 193 | 2016-02-03 | 2023-08-31 |
| Brimonidine Tartrate for the Treatment of Injection Related Erythema peginterferon beta-1a, brimonidine tartrate, Vehicle Gel - Relapsing-Remitting Multiple Sclerosis (RRMS) | Phase 4 | Withdrawn | Biogen | 2016-02-01 | 2016-04-25 | |
| Plegridy Observational Program peginterferon beta-1a - Relapsing Forms of Multiple Sclerosis | Completed | Biogen | 1208 | 2014-11-12 | 2022-09-26 | |
| Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers peginterferon beta-1a, Rebif - Multiple Sclerosis | Phase 1 | Completed | Biogen | 30 | 2014-10-01 | 2015-02-02 |
| Pharmacokinetic Study of Peginterferon Beta-1a in Japanese and Caucasian Adult Healthy Participants. Peginterferon Beta-1a - Healthy | Phase 1 | Completed | Biogen | 44 | 2013-12-01 | 2015-01-09 |
| Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017) BIIB017, naproxen - Relapsing Multiple Sclerosis | Phase 3 | Completed | Biogen | 251 | 2013-11-01 | 2017-01-25 |
| Biogen Multiple Sclerosis Pregnancy Exposure Registry Dimethyl fumarate, Peginterferon beta-1a - Multiple Sclerosis, Exposure During Pregnancy | Completed | Biogen | 408 | 2013-10-30 | 2022-06-21 | |
| Long-Term Safety and Efficacy Study of Peginterferon Beta-1a peginterferon beta-1a - Relapsing Multiple Sclerosis | Phase 3 | Completed | Biogen | 1077 | 2011-04-01 | 2017-01-13 |
| Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis BIIB017 (peginterferon beta-1a), Placebo - Relapsing Multiple Sclerosis | Phase 3 | Completed | Biogen | 1516 | 2009-06-01 | 2014-09-19 |
Multiple Sclerosis (6) · Multiple Sclerosis, Relapsing-Remitting (5) · Injection Site Reaction (3) · Recurrence (3) · COVID-19 (1) · Demyelinating Diseases (1) · Erythema (1) · Severe Acute Respiratory Syndrome (1)
Biogen (12) · Holy Name Medical Center, Inc. (1) · Pontificia Universidad Catolica de Chile (1)
United States (9) · Germany (6) · France (5) · Spain (5) · United Kingdom (5) · Canada (4) · Italy (4) · Australia (3) · Belgium (3) · Bulgaria (3) · Chile (3) · Colombia (3) · Croatia (3) · Czechia (3) · Estonia (3)
Arturo Borzutzky, MD (1) · Carolina Iturriaga, NP (1) · Cecilia Perret, MD (1) · Diego Garcia-Huidobro, MD,PhD (1) · Eleanor N Fish, PhD (1) · Jose A Castro-Rodriguez, MD,PhD (1) · Stephen Stick, MD,PhD (1) · Tobias Kollmann, MD,PhD (1)
PMID 15304586, PMID 17588298, PMID 24794721, PMID 25073663, PMID 25265472, PMID 25432952, PMID 25551571, PMID 26195056, PMID 27060836, PMID 28183276, PMID 28450894, PMID 28607743, PMID 29104758, PMID 30181780, PMID 33307998, PMID 34388972, PMID 34815321, PMID 37538539, PMID 37652990, PMID 9633761
2015 (2), 2018 (2), 2008 (1), 2023 (1)